Evidence map›Paper›PMID 34012520›Full record

ArticleAvicenna journal of medical biotechnology

Designing and Development of a Tandem Bivalent Nanobody against VEGF

Farnaz Khodabakhsh, Morteza Salimian, Pardis Ziaee, Fatemeh Kazemi-Lomedasht, Mahdi Behdani, Reza Ahangari Cohan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. VInternational journal of molecular sciences · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Farnaz KhodabakhshDepartment of Genetics and Advanced Medical Technology, Medical Biotechnology Research Center, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Morteza SalimianDepartment of Medical Laboratory, Kashan University of Medical Sciences, Kashan, Iran.
Pardis ZiaeeDepartment of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Fatemeh Kazemi-LomedashtVenom and Biotherapeutics Molecules Laboratory, Department of Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mahdi BehdaniVenom and Biotherapeutics Molecules Laboratory, Department of Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Reza Ahangari CohanDepartment of Nanobiotechnology, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInhibition of angiogenesis using monoclonal antibodies is an effective strategy in cancer therapy. However, they could not penetrate sufficiently into solid tumors. Antibody fragments have solved this issue. However, they suffer from short in vivo half-life. In the current study, a tandem bivalent strategy was used to enhance the pharmacokinetic parameters of an anti-VEGF165 nanobody.

methodsHomology modeling and MD simulation were used to check the stability of protein. The cDNA was cloned into pHEN6C vector and the expression was investigated in WK6

resultsRMSD analysis revealed the tandem bivalent nanobody had good structural stability after 50

conclusionOur data revealed that the physicochemical as well as

Indexed as

CancerPharmacokineticsSingle domain antibodyVascular endothelial growth factor

Identifiers

PMID34012520
PMCPMC8112138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.